Eczema affects millions of people, particularly children under the age of six. First time a complex biologic drug like this has been tested on this age group. In a new study, 162 North American and European kids between the ages of 6 months and 6 years with moderate-to-severe eczema were given dupilumab or a placebo across the course of 16 weeks. It’s now available to children as young as 6 months, and a parent or healthcare professional can administer the drug through a monthly shot.Read Long Article
